Eiger BioPharmaceuticals Inc EIGR

Healthcare Biotechnology

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.

NDAQ:EIGR - Post by User

Eiger BioPharmaceuticals Inc

Bullboard Posts

Post by stockfloweron Jul 14, 2017 7:07pm

414 Views

Post# 26471676

200 Day Moving Average is 0.13 Cents Away!

We are 0.13 cents away from the 200 day moving average! At that point everyone should be confident that share prices will be increasing. I sold today and regretted it and got back in. Earnings are approaching in August. If you look back a year ago at the technical charts, you will see that this stock should have triple the valuation from what it currently is. Even repected analysts noticed this. On March 9, 2015, a share price of 400.35 was reached. I am optimistic that a minimum 10% increase per week will occur until the official earnings release.

Bullboard Posts

PharmAla Biotech launches educational portal for MDMA